Plant biotechnology company 22nd Century Group Inc (NYSE American:XXII) reported on Friday the election of Michael J. Zercher as its chief operating officer.
In his new position, Zercher will lead 22nd Century Group's marketing, sales, business development, research and development, regulatory affairs and operations.
The company aims to support the US FDA in implementing a new Agency rule requiring that all cigarettes sold in the US contain only minimally or non-addictive levels of nicotine; obtain a Modified Risk Tobacco Product (MRTP) marketing order from the FDA for the VLNC cigarettes; launch its proprietary VLNC cigarettes in the US and internationally; develop its hemp/cannabis intellectual property portfolio; and expand its presence in the hemp/cannabis industry.
Prior to the promotion, Zercher was employed as the vice president of Business Development in the company, which he joined in October 2016.
Previously, Zercher has served as vice president and managing director of Santa Fe Natural Tobacco Company's (SFNTC) international business, a subsidiary of Reynolds American Inc and the corporate home of the Natural American Spirit tobacco brand, as well as the owner of Santa Fe Hard Cider LLC based in Santa Fe, NM.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval